Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew C Harris

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Blood Advances|May 31, 2018
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabineAndrew C Harris, Jaap J Boelens, Kwang Woo Ahn, et al.
British Journal of Haematology|January 11, 2024
Donor-specific antibody desensitization with daratumumab prior to haematopoietic cell transplant for sickle cell disease: A case reportBinni Kunvarjee, Gloria Paz Contreras Yametti, Amanda G Blouin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
The New England Journal of Medicine|August 9, 2013
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathMark T Vander Lugt, Thomas M Braun, Samir Hanash, et al.
Transplantation and Cellular Therapy|August 31, 2022
Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE StudyPaul A Carpenter, Hyoung Jin Kang, Keon Hee Yoo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2015
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortalityMargaret L MacMillan, Marie Robin, Andrew C Harris, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2015
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumAndrew C Harris, Rachel Young, Steven Devine, et al.
Bone Marrow Transplantation|February 27, 2025
Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002Gabrielle Meyers, Mehdi Hamadani, Michael Martens, et al.
Bone Marrow Transplantation|September 25, 2023
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002Gabrielle Meyers, Mehdi Hamadani, Michael Martens, et al.
Blood Advances|November 9, 2021
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantationMuna Qayed, Benjamin Watkins, Scott Gillespie, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Blood Advances|May 31, 2018
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabineAndrew C Harris, Jaap J Boelens, Kwang Woo Ahn, et al.
British Journal of Haematology|January 11, 2024
Donor-specific antibody desensitization with daratumumab prior to haematopoietic cell transplant for sickle cell disease: A case reportBinni Kunvarjee, Gloria Paz Contreras Yametti, Amanda G Blouin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
The New England Journal of Medicine|August 9, 2013
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathMark T Vander Lugt, Thomas M Braun, Samir Hanash, et al.
Transplantation and Cellular Therapy|August 31, 2022
Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE StudyPaul A Carpenter, Hyoung Jin Kang, Keon Hee Yoo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2015
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortalityMargaret L MacMillan, Marie Robin, Andrew C Harris, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2015
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumAndrew C Harris, Rachel Young, Steven Devine, et al.
Bone Marrow Transplantation|February 27, 2025
Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002Gabrielle Meyers, Mehdi Hamadani, Michael Martens, et al.
Bone Marrow Transplantation|September 25, 2023
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002Gabrielle Meyers, Mehdi Hamadani, Michael Martens, et al.
Blood Advances|November 9, 2021
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantationMuna Qayed, Benjamin Watkins, Scott Gillespie, et al.
Pageof 10